Home Reproductive and Prenatal Genetic Tests Prenatal Chromosomal Microarray Test: Deletions, Duplications, and Results

Prenatal Chromosomal Microarray Test: Deletions, Duplications, and Results

By
Vita Library
-
2
Prenatal chromosomal microarray testing detects fetal chromosome deletions and duplications. Learn when CMA is used, how results and VUS are interpreted, and its limits.

A prenatal chromosomal microarray test examines fetal DNA for missing or extra chromosome material, including changes too small to be seen on a standard chromosome picture. These changes are called copy-number variants, or CNVs, and may involve a deletion, in which a segment is missing, or a duplication, in which an additional copy is present. Chromosomal microarray analysis is a diagnostic test, not a blood-based screening test. It is performed on fetal or placental cells obtained through chorionic villus sampling, amniocentesis, or, in selected circumstances, testing of fetal tissue. It is especially valuable when ultrasound identifies one or more structural differences, although it may also be discussed for other pregnancies undergoing invasive diagnosis. A result may provide a clear explanation, be reassuring within the test’s limits, or identify a finding whose health effects cannot yet be predicted confidently. Understanding what the test can detect—and what it cannot—is essential before deciding whether it fits a pregnancy’s clinical situation and the family’s goals.

  • Prenatal chromosomal microarray is a diagnostic DNA test for chromosome gains and losses; it is not the same as cell-free DNA screening.
  • It can detect many clinically important deletions and duplications that are below the resolution of a standard karyotype.
  • Testing requires a fetal or placental sample, usually from chorionic villus sampling or amniocentesis.
  • Results are commonly classified as pathogenic, likely pathogenic, uncertain, likely benign, or benign.
  • A normal result does not exclude every genetic condition, balanced chromosome rearrangement, or single-gene disorder.
  • Pretest and post-test genetic counseling are particularly useful because uncertain, inherited, or unexpected findings may require individualized interpretation.

Table of Contents

What prenatal chromosomal microarray detects

Chromosomal microarray analysis, often abbreviated CMA, measures whether selected regions across the fetal genome are present in the expected amount. Human cells usually contain two copies of most autosomal DNA—one inherited from each parent. A microarray can identify a region with only one copy, called a deletion, or three copies, called a duplication. The collective term for these gains and losses is copy-number variant.

The word “micro” can be misleading. It does not mean that every tiny DNA change is detectable. It means the platform can identify chromosome imbalances at a much finer resolution than a conventional prenatal karyotype. A karyotype examines chromosomes under a microscope and is best at showing whole-chromosome changes and large structural rearrangements. A microarray examines DNA at thousands or millions of genomic locations and can find submicroscopic CNVs, sometimes spanning a fraction of the DNA required for a visible chromosome change.

Two broad platform types are used. Array comparative genomic hybridization compares the patient’s DNA signal with reference DNA to find gains and losses. Single-nucleotide polymorphism, or SNP, arrays also evaluate copy number but add information about patterns of genetic similarity. Depending on the laboratory design and validation, a SNP array may reveal long regions of homozygosity, possible parental relatedness, some forms of uniparental disomy, and certain whole-genome copy patterns such as triploidy. An array-CGH platform usually cannot identify these copy-neutral patterns. The report should name the technology, resolution, and relevant limitations.

CMA can detect many established genomic disorders, such as 22q11.2 deletion syndrome, 1p36 deletion syndrome, Williams syndrome, and recurrent deletions or duplications involving regions such as 16p11.2. It can also define the size and gene content of an imbalance more precisely than a karyotype. Size alone, however, does not determine severity. A small CNV that disrupts a dosage-sensitive gene may be clinically important, while a larger CNV in a region tolerant of copy-number change may be benign.

The test may also detect mosaicism, meaning that the tested sample contains more than one cell line, if the abnormal cell line is present above the laboratory’s detection threshold. Sensitivity varies by platform, chromosome region, sample quality, and the percentage of abnormal cells. A negative array therefore does not rule out low-level mosaicism.

Most importantly, CMA is a copy-number test. It does not generally read each DNA letter. A fetus can have a pathogenic single-gene variant, repeat expansion, methylation disorder, or other molecular change despite a normal microarray result.

When the test is considered

Prenatal chromosomal microarray is most strongly considered when invasive diagnostic testing is being performed because ultrasound has shown one or more major fetal structural anomalies. Examples include certain heart defects, brain malformations, skeletal abnormalities, kidney differences, growth concerns accompanied by other findings, or abnormalities affecting multiple organ systems. In that setting, CMA can identify clinically significant submicroscopic CNVs that a karyotype would miss.

The chance of an informative result depends heavily on the fetal phenotype. A carefully performed ultrasound examination and clear description of the findings help the laboratory and genetics team assess whether a detected CNV plausibly explains what is seen. Multiple anomalies or a recognizable pattern may raise the diagnostic yield, but a single isolated finding can also be associated with a pathogenic CNV. Published yields vary because studies use different inclusion criteria, platforms, and definitions of clinically significant findings.

CMA may also be discussed when a person chooses chorionic villus sampling or amniocentesis after a positive prenatal screen, increased nuchal translucency, a previous affected pregnancy, or another reason for definitive chromosome testing. When no fetal structural anomaly is present, professional guidance generally supports counseling about both microarray and karyotype rather than assuming that one test is automatically right for everyone. The added resolution of CMA must be weighed against its greater possibility of revealing an uncertain or unexpected finding.

A positive cell-free DNA result does not by itself establish a fetal diagnosis. If screening suggests trisomy 21, trisomy 18, trisomy 13, a sex chromosome condition, or a copy-number change, diagnostic sampling is needed before irreversible pregnancy decisions. The diagnostic laboratory may recommend rapid aneuploidy testing, karyotype, CMA, or a combination based on the suspected condition. For example, a karyotype can show whether a common trisomy is caused by a free extra chromosome or a translocation, information that can affect recurrence counseling. CMA can confirm the extra chromosome material but may not define a balanced structural mechanism.

The test can also be useful after fetal death or stillbirth when sufficient fetal DNA is available. Unlike karyotyping, microarray does not always require living dividing cells, so it may succeed when culture fails. Maternal cell contamination and tissue selection still require careful attention.

CMA is not a routine substitute for every form of prenatal screening. It requires an invasive procedure during an ongoing pregnancy, and it can generate information whose meaning is incomplete. The decision is preference-sensitive. Some families want the broadest available chromosome-level diagnosis; others prioritize avoiding uncertain findings or procedure-related risk. Good counseling addresses both choices without presenting testing as mandatory.

How samples are collected and tested

Prenatal CMA requires DNA that represents the pregnancy. The two main collection procedures are chorionic villus sampling, generally performed in the first trimester, and amniocentesis, usually performed after the first trimester. CVS obtains placental villi. Amniocentesis obtains amniotic fluid containing fetal cells. Timing, procedural risks, access, ultrasound findings, and how soon results are needed influence the choice.

Because CVS analyzes placental tissue, a result may occasionally reflect confined placental mosaicism rather than the fetus. If mosaicism or an unexpected chromosome pattern is detected, amniocentesis may be recommended to clarify the fetal result. This distinction is particularly important after a cell-free DNA screen, which also primarily reflects placental DNA.

The laboratory extracts DNA from uncultured cells when possible. Some samples require cell culture because of low quantity, contamination, or another technical issue. Culture can lengthen turnaround and, rarely, alter the apparent proportion of mosaic cells. Laboratories may perform maternal cell contamination studies, especially for amniotic fluid with blood, fetal tissue, or results that could be confused with maternal DNA. A maternal blood sample may therefore be requested along with the fetal sample.

The DNA is applied to a microarray containing genomic probes. Computer analysis compares signal intensity across the genome with expected patterns. The laboratory then evaluates any CNV using multiple evidence sources: the genes involved, known dosage-sensitive regions, population databases, published cases, inheritance, fetal findings, and technical quality. This interpretive step is as important as the instrument’s ability to detect the change.

Many laboratories use a prenatal reporting threshold that differs from a postnatal threshold. A platform might technically detect very small changes but report only those meeting validated size, gene-content, or clinical-significance criteria. Targeted high-density coverage may be used in known disease regions. Consequently, “microarray” is not a single universal test; two laboratories can differ in probe design, resolution, reporting policy, and whether they disclose uncertain findings.

Turnaround time often ranges from roughly one to three weeks, but it varies. Additional testing, parental samples, cell culture, confirmation, or complex interpretation can extend the timeline. Rapid testing for common aneuploidies may be reported sooner when medically indicated, but a rapid result does not replace the full microarray analysis.

Before the procedure, the consent discussion should address what categories of results the laboratory reports, whether parental testing may be requested, how unexpected biological relationships or regions of homozygosity are handled, and whether the family can limit certain findings. Policies vary by country and laboratory. Asking these questions before sampling is easier than making decisions after an unexpected report arrives.

How results are classified

A prenatal microarray report typically assigns each reported CNV to one of five evidence-based categories. The category describes current evidence about the variant, not a complete prediction of the child’s future.

Pathogenic means there is strong evidence that the CNV causes disease or a recognized genomic disorder. Likely pathogenic means the evidence strongly favors a disease association but does not meet the laboratory’s threshold for definitive classification. Both categories may explain ultrasound findings, indicate risks that are not visible prenatally, or identify a condition with variable expression.

A variant of uncertain significance, or VUS, is a CNV for which available evidence is insufficient or conflicting. It is not a positive diagnosis, and it should not be treated as harmless or harmful simply because it appears on a report. The uncertainty may involve whether the CNV affects health at all, which features it might influence, or how penetrant and severe those features may be. A dedicated explanation of a variant of uncertain significance can help families understand why this category often changes with new evidence.

Likely benign and benign CNVs are considered unlikely to cause disease. Many laboratories do not include common benign variation in the main prenatal report, although it may be present in technical data. Reporting practices differ, so an apparently “normal” report means no reportable abnormality was found under that laboratory’s criteria.

Reports may use cytogenomic notation that looks unfamiliar, such as arr[genome build] 22q11.21(start_end)x1. In simplified terms, arr indicates microarray analysis, the genome build identifies the reference coordinates, the chromosome band and numbers locate the segment, and x1 indicates one copy instead of the usual two. A duplication may be marked x3. The report usually provides a plain-language interpretation, but a genetics professional can translate the notation and explain what evidence supports the classification.

A normal, negative, or no clinically significant copy-number change detected result is reassuring for the types of imbalance the assay can detect. It does not certify that the fetus has no genetic condition or health problem. The ultrasound findings, family history, and limits of the platform still matter. When significant anomalies remain unexplained, a clinician may discuss sequencing or another targeted test rather than repeating a microarray.

A report can also identify a whole-chromosome gain or loss, a large segmental imbalance, suspected mosaicism, or a region of homozygosity. These findings may need confirmation or a different test to establish the chromosome structure, fetal distribution, or clinical significance.

Interpreting deletions, duplications, and VUS

Interpretation begins with four questions: What genomic region is involved? Which genes are dosage-sensitive? Is the change new in the fetus or inherited? Does it fit the ultrasound and family findings? No single answer is sufficient on its own.

For a known recurrent deletion or duplication syndrome, the laboratory may have substantial data from many affected individuals. Even then, the prenatal phenotype may be incomplete. Some features develop only after birth, and ultrasound cannot assess cognition, learning, behavior, hearing, or many age-dependent medical risks. The same CNV can cause severe effects in one person and mild or no obvious effects in another. This variable expressivity limits precise prediction.

Parental testing can be highly informative. A de novo CNV—one not found in either tested parent—may strengthen evidence that it is clinically significant, particularly when it disrupts dosage-sensitive genes and matches the fetal findings. An inherited CNV from a healthy parent may lower concern in some circumstances, but it does not automatically prove benignity. The parent may have subtle features, reduced penetrance may allow some carriers to remain unaffected, or the fetus may be affected differently. Conversely, an inherited pathogenic CNV can confirm a familial condition and clarify recurrence risk.

For a VUS, parental studies may help reclassify the finding or narrow the counseling range. They may also reveal that a parent carries the same uncertain change, creating implications for the parent and relatives. Families should know that parental testing can produce information beyond the immediate pregnancy and may not eliminate uncertainty.

The term “microdeletion” does not mean mild, and “large deletion” does not guarantee a severe outcome. Clinical effect depends on genomic content, inheritance, penetrance, and the particular genes affected. Duplications can also be pathogenic, but their effects may differ from deletion of the same region because extra dosage and missing dosage alter biology differently.

A VUS should be interpreted using current laboratory and clinical evidence rather than internet anecdotes or a single case report. Databases may contain individuals with different CNV boundaries, different genes, or incomplete clinical descriptions. Prenatal findings add another challenge because some features cannot be assessed before birth. A multidisciplinary discussion involving maternal-fetal medicine, clinical genetics, laboratory genetics, pediatric subspecialists, and the family can be valuable for complex results.

Classification can change. New population data, functional evidence, or reports of additional individuals may move a VUS toward benign or pathogenic. Reanalysis is not always automatic. Families can ask the laboratory or genetics clinic whether reinterpretation is available, when it would be reasonable, and how updated contact information should be maintained. A 2025 cohort study of children with prenatally identified VUS reported substantial reclassification over time, illustrating that uncertainty is often dynamic rather than permanent.

Microarray versus other prenatal tests

CMA is one component of prenatal genetic evaluation, and choosing it requires understanding the distinct question each test answers.

Cell-free DNA screening: A maternal blood test estimates the chance of selected chromosome conditions using placental DNA fragments. It is highly informative for common trisomies but remains screening. Expanded panels for microdeletions and genome-wide CNVs have different performance and can produce false-positive or false-negative results. CMA on CVS or amniotic fluid is diagnostic for reportable copy-number changes in the tested sample.

Karyotype: A karyotype shows the number and visible structure of chromosomes. It detects whole-chromosome aneuploidy and large imbalances and can identify balanced translocations or inversions. CMA provides much higher resolution for gains and losses but usually cannot show a balanced rearrangement because no DNA is missing or extra. It may detect an unbalanced product of a translocation without revealing the precise structural arrangement. Karyotyping one or both parents may then be needed.

Rapid aneuploidy testing: Fluorescence in situ hybridization, quantitative fluorescent PCR, or another rapid method can answer a focused question about common chromosome abnormalities within a shorter timeframe. It does not provide the genome-wide resolution of CMA. A rapid normal result can therefore be followed by an abnormal microarray result.

Targeted testing: If ultrasound or family history strongly suggests a specific condition caused by a known gene variant, targeted molecular testing may be more appropriate than, or added to, CMA. A normal array does not rule out a sequence-level variant in that gene.

Prenatal exome sequencing: Exome sequencing evaluates the protein-coding regions of many genes, primarily for sequence variants. It is often considered when one or more significant fetal anomalies remain unexplained after karyotype or CMA. A large 2022 systematic review found a substantial additional diagnostic yield in carefully selected fetuses with structural anomalies after standard chromosome testing was nondiagnostic, although the yield varies widely by phenotype and case selection. The prenatal exome sequencing test also introduces its own limitations, uncertain variants, and consent issues.

Genome sequencing: This broader approach may detect sequence variants, some CNVs, and certain structural changes in one analysis, but availability, validation, turnaround, interpretation, and prenatal reporting standards vary. In many settings, CMA remains an established first-line genomic test for fetal structural anomalies.

No single test detects every clinically important genetic change. Combining tests indiscriminately can increase cost, uncertainty, and incidental findings. The most efficient strategy starts with the phenotype, screening history, gestational timing, family history, and the decisions the result could affect.

Limitations, next steps, and counseling

The principal limitation of CMA is that it detects genomic dosage, not all forms of genetic variation. Most balanced translocations and inversions are invisible. Single-nucleotide variants, small insertions and deletions below the platform’s resolution, repeat expansions, many mitochondrial variants, and most methylation or imprinting disorders require other methods. Array-CGH may miss triploidy, while SNP-based arrays may detect it; the laboratory’s platform matters.

A normal result also cannot predict all congenital, developmental, or pregnancy outcomes. Some fetal anomalies are caused by non-genetic factors, multifactorial influences, infections, placental problems, or genetic mechanisms outside the assay. Ultrasound follow-up remains important regardless of the array result.

Mosaicism can complicate interpretation. The abnormal cell line may be present in the placenta but not the fetus, in the fetus but below the assay threshold, or at different levels in different tissues. Confirmation with amniocentesis, karyotype, FISH, or another method may be recommended. Maternal cell contamination can also obscure fetal results if not recognized.

SNP arrays can reveal long stretches in which both chromosome copies appear genetically identical. This may suggest parental relatedness or uniparental disomy, depending on the pattern. Such findings can raise the possibility of recessive disease or imprinting disorders, but they usually require additional evaluation. Laboratories differ in whether and how they report them.

When a pathogenic or likely pathogenic CNV is found, next steps often include a detailed ultrasound, fetal echocardiography or other targeted imaging, parental testing, and consultation with specialists familiar with the condition. Counseling should cover the full known outcome range, including uncertainty, rather than presenting only the most severe published cases. The family may use the information to prepare for neonatal care, pursue additional testing, consider pregnancy-management options, or decide that no further action is desired.

When the result is a VUS, the most useful next step is usually expert interpretation rather than urgent action based on the label alone. Parental studies, review of the exact CNV boundaries, correlation with ultrasound, and discussion of reporting evidence may clarify the finding. Pregnancy decisions should not rest solely on an uncertain variant without careful counseling.

When CMA is normal but structural anomalies persist, the team may revisit the phenotype and consider targeted gene testing, a gene panel, exome sequencing, infection studies, or other evaluations. A normal CMA meaningfully narrows some possibilities; it does not end the diagnostic process.

Before testing, families benefit from deciding what they hope to learn and what kinds of uncertainty they are willing to receive. After testing, they deserve a result discussion that separates what is known, what is inferred, and what remains unknown. Prenatal chromosomal microarray is powerful precisely because it sees more than a karyotype. That same breadth makes informed consent and individualized interpretation central to responsible use.

References

Disclaimer

This article provides general educational information and is not a substitute for personalized medical care, genetic counseling, or advice from a maternal-fetal medicine specialist. Test availability, reporting policies, procedure timing, and interpretation vary by laboratory and healthcare system. Decisions about prenatal diagnosis should be made with qualified clinicians who can integrate the complete ultrasound, family history, pregnancy history, and personal values.

RELATED ARTICLESMORE FROM AUTHOR